Skip to main content

Advertisement

SpringerLink
Log in

The Economic and Quality-of-Life Burden of Crohn’s Disease in Europe and the United States, 2000 to 2013: A Systematic Review

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Crohn’s disease (CD) is associated with a substantial healthcare burden that affects the patient, healthcare systems and society in general.

Aim

To provide a systematic evaluation of published data relating to the economic and health-related quality-of-life (HRQoL) burden of CD in selected European countries (Germany, France, UK, Italy, Spain) and the USA since 2000.

Methods

We undertook a systematic review of publications relating to CD, its economic burden and impact on HRQoL. Research questions focused on the disease costs from a societal perspective and HRQoL burden in adults and pediatric/adolescent patients according to disease stage/severity. Total, direct and indirect costs were identified, as well as the impact of CD on HRQoL measured using both generic and disease-specific instruments.

Results

Overall, 61 publications met the research criteria (38 on costs, 23 on HRQoL). CD in the USA and Europe together was associated with annual total costs of nearly €30 billion, more than half due to indirect costs. HRQoL was consistently and statistically significantly lower among CD patients compared with normal populations, due to physical, emotional and social effects.

Conclusions

CD is a global health problem with high societal costs and substantial HRQoL burden. High-value care pathways including cost-effective therapies will help to induce and maintain remission, reduce complications of disease and improve HRQoL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–1794.

    Article  PubMed  Google Scholar 

  2. Isaacs KL. How rapidly should remission be achieved? Dig Dis. 2010;28:548–555.

    Article  PubMed  Google Scholar 

  3. De Buck van Overstraeten A, Wolthuis A, D’Hoore A. Surgery for Crohn’s disease in the era of biologicals: a reduced need or delayed verdict? World J Gastroenterol. 2012;18:3828–3832.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Cheifetz AS. Management of active Crohn disease. JAMA. 2013;309:2150–2158.

    Article  CAS  PubMed  Google Scholar 

  5. Ezri J, Marques-Vidal P, Nydegger A. Impact of disease and treatments on growth and puberty of pediatric patients with inflammatory bowel disease. Digestion. 2012;85:308–319.

    Article  CAS  PubMed  Google Scholar 

  6. Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs. 2010;24:3–14.

    Article  CAS  PubMed  Google Scholar 

  7. Lev-Tzion R, Turner D. Is pediatric IBD treatment different than in adults? Minerva Gastroenterol Dietol. 2012;58:137–150.

    CAS  PubMed  Google Scholar 

  8. National Institute for Health and Clinical Excellence (NICE). Crohn’s Disease. Management in Adults and Children. London: NICE; 2012.

    Google Scholar 

  9. Sandhu BK, Fell JM, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr. 2010;50:S1–S13.

    Article  PubMed  Google Scholar 

  10. Hommes D, Colombel JF, Emery P, Greco M, Sandborn WJ. Changing Crohn’s disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis. 2012;6:S224–S234.

    Article  PubMed  Google Scholar 

  11. Wilson B, Lonnfors S, Hommes DW, et al. A European Crohn’s and ulcerative colitis patient life IMPACT survey. J Crohn’s Colitis. 2012;6:S171.

    Article  Google Scholar 

  12. Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31:693–707.

    Article  CAS  PubMed  Google Scholar 

  13. Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol. 2012;18:3839–3848.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The costs of Crohn’s disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008;24:319–328.

    Article  CAS  PubMed  Google Scholar 

  15. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn’s disease and ulcerative colitis. J Occup Environ Med. 2008;50:1261–1272.

    Article  PubMed  Google Scholar 

  16. Cohen RD, Waters HC, Tang B, Rahman MI. Effects of fistula on healthcare costs and utilization for patients with Crohn’s disease treated in a managed care environment. Inflamm Bowel Dis. 2008;14:1707–1714.

    Article  PubMed  Google Scholar 

  17. Stark R, Konig HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics. 2006;24:797–814.

    Article  PubMed  Google Scholar 

  18. Benedini V, Caporaso N, Corazza GR, et al. Burden of Crohn’s disease: economics and quality of life aspects in Italy. Clin Outcomes Res. 2012;4:209–218.

    Google Scholar 

  19. Juan J, Estiarte R, Colome E, Artes M, Jimenez FJ, Alonso J. Burden of illness of Crohn’s disease in Spain. Dig Liver Dis. 2003;35:853–861.

    Article  CAS  PubMed  Google Scholar 

  20. Lichtenstein GR, Cuffari C, Kane SV, Hanauer S, Present DH. Maintaining remissions across the lifespan: a roundtable with Crohn’s disease experts. Inflamm Bowel Dis. 2004;10:S11–S21.

    Article  PubMed  Google Scholar 

  21. Gomollon Garcia F, Gonzalez Lama Y, et al. Work productivity and activity impairment in Spanish Crohn’s disease patients. J Crohns Colitis. 2012;6:S115.

    Article  Google Scholar 

  22. Dorrian A, Dempster M, Adair P. Adjustment to inflammatory bowel disease: the relative influence of illness perceptions and coping. Inflamm Bowel Dis. 2009;15:47–55.

    Article  PubMed  Google Scholar 

  23. Albert JG, Kotsch J, Kostler W, et al. Course of Crohn’s disease prior to establishment of the diagnosis. Z Gastroenterol. 2008;46:187–192.

    Article  CAS  PubMed  Google Scholar 

  24. Button LA, Roberts SE, Goldacre MJ, Akbari A, Rodgers SE, Williams JG. Hospitalized prevalence and 5-year mortality for IBD: record linkage study. World J Gastroenterol. 2010;16:431–438.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004;53:1471–1478.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Prenzler A, Bokemeyer B, Von Der Schulenburg JM, Mittendorf T. Health care costs and their predictors of inflammatory bowel diseases in Germany. Eur J Heal Econ. 2011;12:273–283.

    Article  Google Scholar 

  27. Ebinger M, Leidl R, Thomas S, et al. Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital. J Gastroenterol Hepatol. 2004;19:192–199.

    Article  PubMed  Google Scholar 

  28. Heaton PC, Tundia NL, Schmidt N, Wigle PR, Kelton CM. National burden of pediatric hospitalizations for inflammatory bowel disease: results from the 2006 Kids’ Inpatient Database. J Pediatr Gastroenterol Nutr. 2012;54:477–485.

    Article  PubMed  Google Scholar 

  29. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–1913.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Odes S, Vardi H, Friger M, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006;131:719–728.

    Article  PubMed  Google Scholar 

  31. Buchanan J, Wordsworth S, Ahmad T, et al. Managing the long term care of inflammatory bowel disease patients: the cost to European health care providers. J Crohns Colitis. 2011;5:301–316.

    Article  PubMed  Google Scholar 

  32. Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci. 2012;57:3080–3091.

    Article  PubMed  Google Scholar 

  33. Reinshagen M, Bokemeyer B, Krummenerl T, et al. Quality of life of Crohn’s disease patients under immunosuppressive therapy in Germany preliminary results of the DaLi study. J Crohns Colitis. 2013;7:S169.

    Article  Google Scholar 

  34. Casellas F, Arenas JI, Baudet JS, et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis. 2005;11:488–496.

    Article  CAS  PubMed  Google Scholar 

  35. Huaman JW, Casellas F, Borruel N, et al. Cutoff values of the Inflammatory Bowel Disease Questionnaire to predict a normal health related quality of life. J Crohns Colitis. 2010;4:637–641.

    Article  CAS  PubMed  Google Scholar 

  36. Lichtenstein GR, Yan S, Bala M, Hanauer S. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004;99:91–96.

    Article  PubMed  Google Scholar 

  37. Feagan BG, Sandborn WJ, Hass S, Niecko T, White J. Health-related quality of life during natalizumab maintenance therapy for Crohn’s disease. Am J Gastroenterol. 2007;102:2737–2746.

    Article  CAS  PubMed  Google Scholar 

  38. Thaler K, Dinnewitzer A, Oberwalder M, Weiss EG, Nogueras JJ, Wexner SD. Assessment of long-term quality of life after laparoscopic and open surgery for Crohn’s disease. Color Dis. 2005;7:375–381.

    Article  CAS  Google Scholar 

  39. Bastida G, Nos P, Aguas M, et al. The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients. BMC Gastroenterol. 2010;10:26.

  40. Casellas F, Lopez-Vivancos J, Badia X, Vilaseca J, Malagelada JR. Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol. 2001;13:567–572.

    Article  CAS  PubMed  Google Scholar 

  41. Casellas F, Lopez-Vivancos J, Casado A, Malagelada JR. Factors affecting health related quality of life of patients with inflammatory bowel disease. Qual Life Res. 2002;11:775–781.

    Article  PubMed  Google Scholar 

  42. Valentini L, Schaper L, Buning C, et al. Malnutrition and impaired muscle strength in patients with Crohn’s disease and ulcerative colitis in remission. Nutrition. 2008;24:694–702.

    Article  PubMed  Google Scholar 

  43. Perrin JM, Kuhlthau K, Chughtai A, et al. Measuring quality of life in pediatric patients with inflammatory bowel disease: psychometric and clinical characteristics. J Pediatr Gastroenterol Nutr. 2008;46:164–171.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Casellas F, Rodrigo L, Nino P, Pantiga C, Riestra S, Malagelada JR. Sustained improvement of health-related quality of life in Crohn’s disease patients treated with infliximab and azathioprine for 4 years. Inflamm Bowel Dis. 2007;13:1395–1400.

    Article  PubMed  Google Scholar 

  45. Barratt SM, Leeds JS, Robinson K, et al. Reflux and irritable bowel syndrome are negative predictors of quality of life in coeliac disease and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23:159–165.

    Article  PubMed  Google Scholar 

  46. Piche T, Ducrotte P, Sabate JM, et al. Impact of functional bowel symptoms on quality of life and fatigue in quiescent Crohn disease and irritable bowel syndrome. Neurogastroenterol Motil. 2010;22:626+e174–632+e174.

  47. Petrak F, Hardt J, Clement T, Borner N, Egle UT, Hoffmann SO. Impaired health-related quality of life in inflammatory bowel diseases: psychosocial impact and coping styles in a national German sample. Scand J Gastroenterol. 2001;36:375–382.

    Article  CAS  PubMed  Google Scholar 

  48. Graff LA, Vincent N, Walker JR, et al. A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1882–1889.

    Article  PubMed  Google Scholar 

  49. Liu Y, Wu EQ, Bensimon AG, et al. Cost per responder associated with biologic therapies for Crohn’s disease, psoriasis, and rheumatoid arthritis. Adv Ther. 2012;29:620–634.

    Article  CAS  PubMed  Google Scholar 

  50. Sussman DA, Kubiliun N, Mulani PM, et al. Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS). Inflamm Bowel Dis. 2012;18:2043–2055.

    Article  PubMed  Google Scholar 

  51. Waters HC, Vanderpoel JE, Nejadnik B, et al. Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease. J Med Econ. 2012;15:45–52.

    Article  PubMed  Google Scholar 

  52. Khanna R, Levesque BG, Bressler B, et al. Early Combined Immunosuppression for the Management of Crohn’s Disease: A Community-Based Cluster Randomized Trial. Copenhagen: ECCO; 2014 [Abstract OP004].

Download references

Conflict of interest

DF: employed by PHMR: PHMR received an unrestricted grant from Nestlé Health Science S.A. to perform the systematic literature search. SL: employed by PHMR: PHMR received an unrestricted grant from Nestlé Health Science S.A. to perform the systematic literature search. HS: previous employee of Nestle Health Sciences. BGL: Received consulting fees from Prometheus Labs, Santarus Inc., and Nestle Health Sciences, Abbvie and Takeda.

Author information

Authors and Affiliations

  1. PHMR Associates, London, UK

    David N. Floyd & Sue Langham

  2. Nestlé Health Science S.A., Vevey, Switzerland

    Hélène Chevrou Séverac

  3. Academic Research, Robarts Clinical Trials, University of Western Ontario, London, ON, Canada

    Barrett G. Levesque

  4. Division of Gastroenterology, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0956, 92103, USA

    Barrett G. Levesque

Authors
  1. David N. Floyd
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sue Langham
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hélène Chevrou Séverac
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barrett G. Levesque
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barrett G. Levesque.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 17 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Floyd, D.N., Langham, S., Séverac, H.C. et al. The Economic and Quality-of-Life Burden of Crohn’s Disease in Europe and the United States, 2000 to 2013: A Systematic Review. Dig Dis Sci 60, 299–312 (2015). https://doi.org/10.1007/s10620-014-3368-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-014-3368-z

Keywords

Search

Navigation